GetTopicDetailResponse(id=e13d123e25fc, topicName=Tiragolumab, introduction=, content=肝細胞癌 Tiragolumab, image=null, comments=0, allHits=278, url=null, type=0, isShow=1, status=1, isAdmin=null, adminId=5395722, adminEncryptionId=cade5395722, adminName=梅斯管理員, createdBy=cade5395722, createdName=梅斯管理員, createdAvatar=, createdTime=Sun Jan 26 15:43:40 CST 2025, time=2025-01-26, bannerImg=https://img.medsci.cn/202167/1623032167418_5160405.png, bannerImgH5=https://img.medsci.cn/202167/1623032167418_5160405.png, likes=0, followStatus=false, moduleDTOList=null, tagId=438109, tagList=[TagDto(tagId=438109, tagName=Tiragolumab)], ipAttribution=陜西省, topicAdmin=0, lengthMark=0)
[GetTopicListResponse(id=2249699, encodeId=cf292249699b2, content=<a href='/topic/show?id=735a81364b7' target=_blank style='color:#2F92EE;'>#肝細胞癌#</a> <a href='/topic/show?id=e13d123e25fc' target=_blank style='color:#2F92EE;'>#Tiragolumab#</a>, objectTitle=腫瘤緩解患者比例翻4倍，還延長生存期！《柳葉刀》子刊：新藥聯合標準治療，效果更好, objectType=article, longId=860162, objectId=f70386016287, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20231112/1699803768993_5579292.jpg, objectUrl=/article/show_article.do?id=f70386016287, replyNumber=0, likeNumber=45, createdTime=2025-01-26, rootId=0, userName=梅斯管理員, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陜西省, moduleDTOList=[ModuleDTO(moduleId=f70386016287, moduleTitle=腫瘤緩解患者比例翻4倍，還延長生存期！《柳葉刀》子刊：新藥聯合標準治療，效果更好, moduleType=article, hrefUrl=http://ermita.cn/article/show_article.do?id=f70386016287)], followStatus=false, userIsMember=false, type=null, lengthMark=0)]
梅斯管理員
2025-01-26發(fā)表于陜西省
